- Mon To Sat 05 PM - 09 PM
Stroke Treatment
When it comes to neurological emergencies, every second counts. If you are seeking specialized Stroke Treatment in Andheri West, Idika Neuro Clinic offers the rapid, expert intervention necessary to safeguard brain health. Under the dedicated care of Dr. Shruti Agrawal, a highly experienced Neurologist, patients receive a comprehensive approach to stroke management from immediate diagnostic evaluation to personalized long-term rehabilitation plans focused on recovery and excellence.
We help patients manage stroke risk factors such as:
Preventive care is a key part of our comprehensive stroke management program.
Seek emergency medical care immediately. Stroke is time-sensitive, and early treatment improves recovery.
Yes. Managing blood pressure, controlling diabetes, eating healthy, exercising, and avoiding smoking significantly reduce stroke risk.
Recovery varies depending on stroke severity, how quickly treatment was started, and individual health factors. Rehabilitation plays a major role.
Stroke treatment focuses on stabilizing and restoring brain function. Most procedures are not painful.
Many patients regain significant function, especially with early treatment and consistent rehabilitation.
Yes—but the good news is that many recurrent strokes can be prevented.
After a stroke or TIA, the first step is to identify why the stroke happened. Depending on the cause, prevention may involve controlling blood pressure, diabetes and cholesterol, treating carotid disease, using antiplatelet medication, or using anticoagulation when the stroke is related to atrial fibrillation.
The most important principle is: secondary prevention should be cause-specific, not one-size-fits-all.
Atrial fibrillation is an irregular heart rhythm in which the upper chambers of the heart do not beat normally.
This can allow blood to stagnate inside the heart and form a clot. If that clot travels to the brain, it can block a blood vessel and cause an ischemic stroke.
AF is a major stroke risk factor. The presentation highlights that approximately 20–30% of strokes are associated with AF, and AF can increase the risk of stroke several-fold.
And there is an important catch:
You don’t necessarily have to feel AF to have it.
Absolutely. This is one of the most important messages in stroke prevention.
Around 10–40% of people with AF may be asymptomatic, sometimes referred to as “silent AF.”
A person may have no palpitations, breathlessness or chest discomfort—and yet AF may be present intermittently.
This is why a person with an apparently unexplained stroke may need prolonged heart-rhythm monitoring even when the initial ECG is normal.
A normal ECG today does not necessarily mean there was no AF yesterday.
Sometimes, yes.
In patients with ischemic stroke or TIA without previously known AF, the presentation cites recommendations for at least 24 hours of ECG monitoring, followed where possible by continuous monitoring for at least 72 hours.
Depending on the individual case, doctors may consider even longer-duration rhythm monitoring.
This is particularly important when the stroke remains unexplained after the usual investigations.
The hidden culprit may not be visible on a 10-second ECG.
Often, yes—if the person has AF and their overall stroke risk warrants anticoagulation.
Anticoagulants reduce the tendency of blood clots to form. They are different from antiplatelet medicines such as aspirin.
The presentation emphasizes that oral anticoagulation is used for long-term stroke-risk reduction in AF, particularly in patients who have already suffered a stroke or TIA.
Doctors commonly use a risk assessment such as CHA₂DS₂-VASc to estimate stroke risk and decide whether anticoagulation is appropriate.
Not usually when anticoagulation is indicated for AF.
Aspirin is an antiplatelet medicine. Anticoagulants work through a different part of the clotting system and are substantially more effective for preventing AF-related cardioembolic stroke in appropriate patients.
The presentation specifically cites guidelines stating that antiplatelet therapy alone is not recommended for stroke prevention in AF when oral anticoagulation is indicated. It also notes that combining an anticoagulant with an antiplatelet is generally not recommended after stroke unless there is another specific indication.
Warfarin is an older and effective anticoagulant, but it has some practical disadvantages.
It has a relatively narrow therapeutic range, interacts with several foods and medicines, and requires regular INR blood testing and dose adjustments. The presentation also highlights challenges relevant to anticoagulation monitoring in India.
Newer oral anticoagulants—often called DOACs/NOACs—include medicines such as apixaban, dabigatran and rivaroxaban.
In patients with non-valvular AF who are eligible for them, guidelines cited in the presentation recommend NOACs in preference to vitamin-K antagonists such as warfarin, with important exceptions such as mechanical heart valves and moderate-to-severe mitral stenosis.
There is no single “one day fits everyone” answer.
Starting too early can increase the risk of bleeding into the damaged brain. Starting too late may leave the patient exposed to another embolic stroke.
The presentation describes a severity-based approach: anticoagulation may be started earlier after a TIA or small/mild stroke and later after a large or severe stroke, with brain imaging and the presence of hemorrhagic transformation being important considerations.
The exact timing should therefore be decided by the treating stroke/neurology team.
Not necessarily. But these situations require careful individual assessment.
Age, kidney function, blood pressure, previous bleeding, cerebral microbleeds, other medicines and the size/type of previous stroke all influence the balance between clotting and bleeding risks.
The presentation discusses renal and elderly considerations and emphasizes that low body weight, increasing age and certain drug combinations can affect bleeding risk.
Even a high bleeding-risk score should not automatically mean that anticoagulation is stopped. The presentation cites data showing that discontinuing anticoagulation in high-risk AF patients can increase thrombotic events and mortality.
The right question is not “Is there bleeding risk?”
The right question is “How do we reduce bleeding risk while still preventing a potentially devastating stroke?”
No.
An intracranial hemorrhage is a medical emergency and anticoagulation may need to be stopped and reversed urgently. But the long-term decision is more complicated.
For selected patients with AF, anticoagulation may sometimes be restarted after an intracranial hemorrhage—often after several weeks—once the cause or modifiable risk factors for bleeding have been addressed. The presentation cites a 4–8 week window in selected AF patients.
This is a highly individualized decision involving the risk of another ischemic stroke versus another hemorrhage.
Stopping an anticoagulant is sometimes necessary. Stopping it forever is not automatically the answer.
If you or a loved one has experienced stroke symptoms or is at high risk, don’t delay early intervention can save lives and significantly improve recovery outcomes. Idika Neuro Clinic offers expert Stroke Treatment in Andheri West, Mumbai including advanced stroke assessment, acute treatment, rehabilitation support, and compassionate long-term care at every stage of recovery.
© 2026 IDIKA Neuro Clinic | All Rights Reserved.
